LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Strona główna・Stock List・Alkermes PLC

Alkermes PLC

Closed

Sector Healthcare

26.85 -0.04

Buy Sell

Overview

Share price change

24h

Current

Min

26.72

Max

27.13

Key metrics
By Trading Economics
Income	55M 91M
Sales	49M 399M
P/E Sector Avg	7.17 103.001
EPS	0.72
Profit margin	22.891
EBITDA	68M 129M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+28.18 upside

Dividends
By Dow Jones
Next Earnings	23 paź 2024

Market Stats
By TradingEconomics
Market Cap	17M 4.8B
Previous open	26.89
Previous close	26.85

News Sentiment

By Acuity

50%

114 / 365 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

26.75 / 28.31 Support & Resistance

Alkermes PLC Chart

Related News

14 gru 2023, 11:06 UTC

Acquisitions, Mergers, Takeovers

Alkermes Athlone Facility Has About 400 Employees >ALKS

14 gru 2023, 11:06 UTC

Acquisitions, Mergers, Takeovers

Alkermes to Get Cash Payment of $92.5 Million for Facility, Related Assets >ALKS

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

28.18% upside

12 Months Forecast

Average 34.43 USD 28.18%

High 39 USD

Low 28 USD

Based on 8 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Alkermes PLC - Dist in the past 3 months.

Technical Score

By Trading Central

26.75 / 28.31Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

114 / 365 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.